Epiphenomena such as tumor-associated angiogenesis have also been identified as prognostic indicators. Although these markers are not currently being used in the day-to-day management of patients with breast carcinoma, the relative importance of such tumor markers and the role they will play in guiding therapy are rapidly evolving.